- 1 [Category: Study Protocol]
- 2 Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents
- 3 With Suicidal Ideation Associated With Major Depressive Disorder:
- 4 Protocol for a Randomized Controlled Trial
- 5 Deniz Yuruk, MD
- 6 Can Ozger
- 7 Juan F. Garzon, MD
- 8 Jarrod M. Leffler, PhD
- 9 Julia Shekunov, MD
- 10 Jennifer L. Vande Voort, MD
- 11 Michael J. Zaccariello, PhD, LP
- 12 Paul A. Nakonezny, PhD
- 13 Paul E. Croarkin, DO, MS
- 14
- 15
- 16 Author Affiliations: Research Fellow in the Department of Psychiatry and
- 17 Psychology (Yuruk and Garzon), Mayo Clinic School of Graduate Medical
- 18 Education, Mayo Clinic College of Medicine and Science, Rochester,
- 19 Minnesota; Virginia Treatment Center for Children (Leffler), Virginia
- 20 Commonwealth University, Richmond, Virginia; Clinical Research
- 21 Coordinator in the Department of Psychiatry and Psychology (Ozger),
- 22 Department of Psychiatry and Psychology (Shekunov, Vande Voort,
- 23 Zaccariello, and Croarkin), Mayo Clinic Children's Research Center (Vande
- 24 Voort, Zaccariello, and Croarkin), and Mayo Clinic Depression Center
- 25 (Vande Voort and Croarkin), Mayo Clinic, Rochester, Minnesota; and

- 26 Department of Population and Data Sciences (Nakonezny), UT
- 27 Southwestern Medical Center, Dallas, Texas.
- 28 Corresponding Author: Paul E. Croarkin, DO, MS, Department of
- 29 Psychiatry and Psychology, Mayo Clinic, 200 First St SW, Rochester, MN
- 30 55905 (croarkin.paul@mayo.edu).
- 31 Text word count: 6,996
- 32 Abstract word count: 289
- 33 No. of tables: 2
- No. of figures: 1
- 35 No. of boxes: 1
- 36 No. of appendixes: 3
- 37 Short title: aTBS in Suicidal Adolescents
- 38

It is made available under a CC-BY 4.0 International license .

39 Abstract **Background:** Suicide is a leading cause of death in adolescents worldwide. 40 Previous research findings suggest that suicidal adolescents with depression 41 have pathophysiological dorsolateral prefrontal cortex (DLPFC) deficits in 42 γ -aminobutyric acid neurotransmission. Interventions with transcranial 43 magnetic stimulation (TMS) directly address these underlying 44 pathophysiological deficits in the prefrontal cortex. Theta burst stimulation 45 (TBS) is newer dosing approach for TMS. Accelerated TBS (aTBS) 46 47 involves administering multiple sessions of TMS daily as this dosing may be more efficient, tolerable, and rapid acting than standard TMS. 48 **Methods:** This is a randomized, double-blind, sham-controlled trial of 49 sequential bilateral aTBS in adolescents with MDD and suicidal ideation. 50 Three sessions are administered daily for 10 days. During each session, 51 continuous TBS is administered first to the right DPFC, in which 1,800 52 pulses are delivered continuously over 120 seconds. Then intermittent TBS 53 is applied to the left DPFC, in which 1,800 pulses are delivered in 2-second 54 bursts and repeated every 10 seconds for 570 seconds. The TBS parameters 55 were adopted from prior research, with 3-pulse, 50-Hz bursts given every 56 57 200 ms (at 5 Hz) with an intensity of 80% active motor threshold. The comparison group will receive 3 daily sessions of bilateral sham TBS 58 treatment for 10 days. All participants will receive the standard of care for 59 patients with depression and suicidal ideation including daily 60 psychotherapeutic skill sessions. Long-interval intracortical inhibition (LICI) 61 biomarkers will be measured before and after treatment. Exploratory 62 measures will be collected with TMS and electroencephalography for 63 biomarker development. 64

- 65 **Discussion:** This is the first known randomized controlled trial to examine
- 66 the efficacy of sequential bilateral aTBS for treating suicidal ideation in
- adolescents with MDD. Results from this study will also provide
- 68 opportunities to further understand the neurophysiological and molecular
- 69 mechanisms of suicidal ideation in adolescents.
- 70 Trial registration: Investigational device exemption (IDE) Number:
- 71 G200220, ClinicalTrials.gov (ID: NCT04701840). Registered August 6,
- 72 2020.
- 73 https://clinicaltrials.gov/ct2/show/NCT04502758?term=NCT04701840&dra
- 74 w=2&rank=1
- 75
- 76 Keywords: accelerated theta burst stimulation; adolescent; depression;
- 77 neuromodulation; suicidal ideation; suicide; transcranial magnetic
- 78 stimulation
- 79

It is made available under a CC-BY 4.0 International license .

Abbreviations

81 AE, adverse event

80

- 82 aTBS, accelerated theta burst stimulation
- 83 CDRS-R, Children's Depression Rating Scale Revised
- 84 CRF, case report form
- 85 C-SSRS, Columbia–Suicide Severity Rating Scale
- 86 DPFC, dorsolateral prefrontal cortex
- 87 DSMB, Data and Safety Monitoring Board
- 88 EEG, electroencephalography
- 89 EMG, electromyography
- 90 FDA, US Food and Drug Administration
- 91 GABA, γ-aminobutyric acid
- 92 GEE, generalized estimating equation
- 93 HIPAA, Health Insurance Portability and Accountability Act
- 94 IDE, investigational device exemption
- 95 IRB, institutional review board
- 96 LICI, long-interval intracortical inhibition
- 97 LICI-100, LICI at an interstimulus interval of 100 ms
- 98 MDD, major depressive disorder
- 99 MINI-KID, Mini-International Neuropsychiatric Interview for Children and
- 100 Adolescents
- 101 MNAR, missing not at random
- 102 MT, motor threshold
- 103 N45, 45 ms after stimulation
- 104 N100, 100 ms after stimulation
- 105 NDA, US National Institute of Mental Health Data Archive

It is made available under a CC-BY 4.0 International license .

- 106 NIH, US National Institutes of Health
- 107 NIMH, US National Institute of Mental Health
- 108 OR, odds ratio
- 109 PHI, protected health information
- 110 PI, principal investigator
- 111 SAE, serious adverse event
- 112 TBS, theta burst stimulation
- 113 TMS, transcranial magnetic stimulation
- 114 UADE, unanticipated adverse device effect

115

It is made available under a CC-BY 4.0 International license .

116	Introduction
117	Suicide is a leading cause of death in adolescents worldwide [1-3].
118	In the US, 18% of teenagers report seriously considering suicide, 15% have
119	made a suicide plan, and 9% have attempted suicide within the preceding
120	year [4,5]. Effective treatments of suicidal ideation are limited for
121	adolescents with major depressive disorder (MDD) [6-8]. Previous research
122	focused on understanding the risk factors for suicide in adolescents in
123	attempted to reduce their overall suicide rates [4,8-10]. Despite decades of
124	research, however, the predictive value of identified suicide risk factors is
125	low and has not improved substantially [8]. Biological correlates explored to
126	date are also weak predictors of suicidal behaviors [8,11-13]. Little prior
127	research has focused on rapid-acting treatments for adolescents with MDD
128	who are actively struggling with thoughts of suicide or have recently
129	attempted suicide [7,14]. Although some studies explored the antisuicidal
130	effects of alternative treatments in adult populations, a considerable
131	knowledge gap remains regarding treating adolescents at risk for suicide
132	[8,15,16].
133	Suicidal persons have structural, functional, neurophysiological,
134	and neuroplastic alterations in the dorsolateral prefrontal cortex (DPFC) [17-
135	19], and these alterations may be targeted with neurostimulation. Structural
136	alterations and serotonergic dysfunction in the DPFC are associated with

137 lethality of suicide attempts [19-21]. Suicidal persons also have

abnormalities in processing negative emotional stimuli and in activating the

139 DPFC. These findings for DPFC activation vary across studies, suggesting

140 multiple neural phenotypes of suicidality that are poorly understood [19].

141 Previous research findings suggest that suicidal adolescents with depression

It is made available under a CC-BY 4.0 International license .

have pathophysiological DPFC deficits in γ -aminobutyric acid (GABA) 142 function [22-25]. Impaired prefrontal cortical GABAergic inhibitory gating 143 related to depression may reduce an adolescent's control over their thoughts 144 and behaviors and may culminate in suicidal ideation and behaviors 145 [17,26,27]. Interventions with transcranial magnetic stimulation (TMS) 146 directly address these underlying pathophysiological deficits in the DPFC 147 [28,29]. 148 In the past decade, studies of TMS interventions found that 149 bilateral TMS strongly reduced suicidal ideation in adults with MDD 150 [30,31]. Preliminary research involving TMS to treat adolescents' suicidal 151 ideation has shown promising results [14]. Treatment with TMS most likely 152 153 addresses pathological imbalances in prefrontal cortical GABAergic

154 inhibitory function that underlie depression and suicidal ideation in

adolescents [14,22,23,29,32]. Standard 10-Hz TMS, however, does not

typically produce rapid relief from suicidal ideation and depressive

157 symptoms [31,33,34].

A newer type of TMS, termed *theta burst stimulation* (TBS), 158 induces changes in synaptic plasticity more rapidly than standard TMS [35-159 160 40]. Protocols with TBS appear to be safe in adolescents, are more tolerable than standard TMS, and are delivered over approximately 12-minute 161 sessions vs 37-minute sessions with standard TMS [41,42]. TBS was 162 developed by mirroring endogenous hippocampal discharges [37]. In TBS 163 dosing, 3-pulse, 50-Hz bursts are delivered every 200 ms (at 5 Hz). 164 165 Stimulation with intermittent TBS has been shown to produce long-term potentiation-like effects [37,43,44], and continuous TBS reduces cortical 166 excitability [37,45]. In prior studies of sequential bilateral TBS, continuous 167

It is made available under a CC-BY 4.0 International license .

TBS was delivered during each session to the right prefrontal cortex,
followed by intermittent TBS delivered to the left prefrontal cortex [41,46].
This technique is thought to target hypoactivity of the left DPFC and
hyperactivity of the right DPFC associated with MDD and suicidal ideation
[19,47,48]. Prior studies suggest that sequential bilateral TBS approaches
clinically reduce depressive symptoms and suicidal ideation more than
unilateral TBS [30,31,46].

Accelerated TBS (aTBS) dosing delivers multiple daily sessions 175 of TBS [49]. The rationale for accelerated dosing is that multiple 176 stimulations each day will produce faster, greater, and more durable 177 effectiveness than standard, daily TMS sessions. Studies of aTBS dosing for 178 179 adult patients with refractory depression have had encouraging results [36,40]. Few prior studies have investigated the use of TBS and aTBS 180 protocols in adolescents. However, the safety profile for adolescents appears 181 to be similar to that for adults [41]. Prior study findings suggest that repeated 182 TBS sessions safely enhance neurophysiological and clinical changes 183 [41,42,50]. Recent work suggests that aTBS protocols more rapidly and 184 effectively improve depressive symptoms and improve synaptic plasticity in 185 the prefrontal cortex [36,39,40]. These aTBS protocols also overcome many 186 practical limitations of standard TMS [49]. 187 Integrating TMS with electromyography (EMG) or 188 electroencephalography (EEG) in neurophysiological studies facilitates the 189 study of cortical inhibition biomarkers and related neurotransmission [51-190

191 53]. Short-interval intracortical inhibition indexes cortical GABA_A-mediated

- 192 inhibitory neurotransmission, and long-interval intracortical inhibition
- 193 (LICI) indexes the cortical GABA_B-mediated inhibitory neurotransmission

It is made available under a CC-BY 4.0 International license .

[53-55]. Data collected with TMS-EEG may yield more direct measures of 194 prefrontal cortical function, but some contemporary methods are 195 controversial [56-60], and TMS-EEG measures have not been reliably 196 collected in adolescents with depression and suicidal ideation [59]. 197 Conversely, with TMS-EMG, measures of prefrontal cortical function have 198 been extensively studied in adolescents with depression and could easily be 199 implemented in clinical environments [24,51,61-63]. Adolescents with 200 MDD and suicidal behaviors have deficient LICI with related GABA_B 201 impairment [25]. A preliminary study found that in adolescents treated for 202 depression, LICI markers improve, with concurrent decrements in suicidal 203 ideation [64]. Hence, TMS-EMG measures of LICI provide a promising 204 205 biomarker for assessing and treating adolescents with depression and suicidal ideation. 206

207 Objectives

The primary aim of this randomized controlled clinical trial is to 208 compare the efficacy of sequential bilateral aTBS vs sham stimulation for 209 treating suicidal ideation in adolescents with MDD. It is hypothesized that, 210 compared with sham stimulation, sequential bilateral aTBS will provide 211 212 greater improvements in intensity of suicidal ideation over the 10-day treatment course (hypothesis 1a) and over the 12-month follow-up period 213 (hypothesis 1b) and would lead to fewer emergency department visits and 214 fewer hospitalizations related to suicidality during 12-month follow-up 215 (hypothesis 1c). 216

The secondary aim examines LICI, measured with TMS-EMG, as a predictive and target engagement biomarker for suicidality in adolescents with MDD. It is hypothesized cortical inhibition will demonstrate an

It is made available under a CC-BY 4.0 International license .

indirect correlation with severity of suicidal ideation at baseline (hypothesis 220 2a) and over the 10-day treatment (hypothesis 2b). An exploratory aim 221 examines the use TMS integrated with EEG (rather than EMG) to develop 222 measures of cortical inhibition for assessing suicide risk and responsiveness 223 to aTBS in adolescents with MDD (hypothesis 3). This concurrent TMS-224 EEG research will provide opportunities to further our understanding of the 225 neurophysiological and molecular mechanisms of suicidal ideation in 226 adolescents while refining biomarker methodology for future clinical use 227 228 [60,61].

229

Methods

230 Design and Study Setting

This is a randomized, double-blind, sham-controlled trial of sequential bilateral aTBS in adolescents with depression and suicidal ideation. This study follows an experimental medicine approach [65] implemented in an intensive outpatient program setting that supports local emergency departments, an 18-bed adolescent inpatient psychiatry unit, and outpatient clinics. The study is taking place at Mayo Clinic, Rochester,

237 Minnesota, and the schedule of events is shown in the Figure.

238 Eligibility Criteria

This study is enrolling adolescents with MDD and suicidal ideation in both the treatment group and control (sham) group. Both inpatients and outpatients are eligible to participate if they meet the inclusion criteria shown in the Box and have none of the exclusion criteria listed there. Use of antidepressant medication (if recommended by the referring clinician and agreed on by the parent/guardian and patient) is allowed.

245 Intervention

It is made available under a CC-BY 4.0 International license .

246 The TMS system (MagVenture TMS Therapy, MagVenture Inc) used in this study is cleared by the US Food and Drug Administration (FDA) 247 for treatment of MDD in adult patients who did not receive satisfactory 248 improvement from antidepressant medication in the current depressive 249 episode. This TMS protocol delivers intermittent TBS for 3 minutes and is 250 based on a patterned TMS paradigm delivered to the left DPFC at 120% 251 resting motor threshold (MT). It consists of bursts of 3 pulses at 50 Hz with 252 bursts repeated at 5 Hz in a duty cycle of 2 seconds on, 8 seconds off over 3 253 minutes 9 seconds, for a total of 600 pulses. Treatment typically is 254 administered daily for 5 days per week, for 4 to 6 weeks. 255 In the present study, TBS will be delivered on both the right and 256 left DPFC, 3 times daily for 10 days (5 days per week). During each session, 257 continuous TBS, in which 1,800 pulses will be delivered continuously over 258 259 120 seconds, is administered first to the right DPFC. Then intermittent TBS is administered to the left DPFC, with 1,800 pulses delivered in 2-second 260 bursts and repeated every 10 seconds for 570 seconds. The comparison 261 group will receive 3 daily sessions of bilateral sham TBS for 10 days. The 262 system has both active and placebo (sham) coils (MagVenture Cool-B70 263 264 A/P coils, MagVenture Inc). Because of the nature of the accelerated treatment paradigm and the age of the target population (13-18 years), the 265 intensity will be decreased from the usual 120% MT to 80% MT. The TBS 266 parameters were adopted from prior research [41]. 267 During the trial, all participants will receive standard-of-care 268 treatment of depression and suicidal ideation, including daily 269 psychotherapeutic skill sessions during TBS therapy [7,66]. The 10-day 270

It is made available under a CC-BY 4.0 International license .

- psychotherapy treatment program was adapted from a youth suicide
- 272 prevention program [66].
- 273 Discontinuing or Modifying Allocated Interventions
- 274 Participants may withdraw voluntarily from the study at any time.
- 275 The participant stopping rules apply during the 2-week period when the
- 276 participants are receiving the study intervention (active or sham sequential
- 277 bilateral aTBS). These rules do not apply to participants in the naturalistic 1-
- 278 year follow-up portion of the study. Participants will be withdrawn from the
- study by the PI (Principal Investigator) if they have any of the following:
- A seizure
- Treatment-induced mania as confirmed by *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition) definitions
- Psychotic symptoms
- Noncompliance with study procedures
- Illicit drug use or a positive urine drug screen during the study
 Strategies to Improve Adherence to Interventions

All participants will be provided with an intensive, 10-day psychotherapeutic intervention during the trial of sequential bilateral aTBS [41,66,67]. This psychotherapeutic program meets and exceeds both local and national standards of care for depressed adolescents with suicidal ideation.

Our prior experience suggests that the sequential bilateral aTBS protocol in the present study will facilitate participant retention because it is a more pragmatic schedule with 10 treatment days total. Mayo Clinic's neuromodulation research team can offer treatment sessions over the weekend if necessary to accommodate an adolescent's or family's schedule.

It is made available under a CC-BY 4.0 International license .

297 Concomitant Care During the Trial

During the trial, participants will continue to take antidepressant 298 medication if recommended by their referring clinician. Participants are not 299 required to take antidepressant medication for study participation because of 300 ethical, human subject protection, and practical concerns. During the 301 treatment phase, zaleplon, zolpidem, or zopiclone (1 dose nightly) as needed 302 for treatment-emergent insomnia or lorazepam (up to 2 mg/d) for treatment-303 emergent anxiety may be administered for up to 10 doses. The use of 304 alternative hypnotics or anxiolytic compounds requires prior approval from 305 the PI. Hormonal contraceptives are allowed. Short-term treatments of 306 headache, allergy, viral rhinitis, and influenza symptoms will be allowed 307 during the trial. All questions regarding the acceptability of specific 308 medications must be answered by the PI. 309 310 Provisions for Posttrial Care After Withdrawal

The PI will assist with clinical referrals for all participants who voluntarily withdraw from the study or are withdrawn by the research team and PI. Specifically, the PI will offer ongoing clinical care or community referrals depending on the participant's preference.

315 Outcomes

The primary outcome is efficacy of sequential bilateral aTBS vs sham stimulation for reducing suicidal ideation in adolescents with MDD. The primary acute outcome measure is change in the score of the Columbia– Suicide Severity Rating Scale (C-SSRS) severity of ideation subscale [68] over the 10-day treatment. Additional outcome measures include monthly follow-up C-SSRS severity of ideation subscale scores, number of hospitalizations related to suicidal ideation, and number of emergency

It is made available under a CC-BY 4.0 International license .

department visits related to suicidal ideation over the 12-month follow-upperiod.

The secondary outcome is to examine LICI as a predictive and target-engagement biomarker for suicidality in adolescents with MDD. Suicidal ideation will be measured with the C-SSRS severity of ideation subscale, and cortical inhibition will be assessed by using LICI at an interstimulus interval of 100 ms (LICI-100) collected with TMS-EMG at baseline and at the end of the 10-day treatment.

An exploratory outcome is developing TMS-EEG measures of cortical inhibition (TMS-EEG at 45 ms after stimulation [N45] and 100 ms after stimulation [N100]) for assessing suicide risk and responsiveness to aTBS in adolescents with MDD.

335 Participant Timeline

336 The schedule of enrollment, interventions, assessments, and visits is shown in Table 1. The first visit for study participants is a screening visit. 337 At this visit, informed consent and assent will be completed. A medical 338 339 history will be taken, vital signs (pulse, blood pressure, temperature, height, and weight) will be measured, and a physical examination, urine pregnancy 340 test (if applicable), and urine drug screen will be completed. The 341 participant's parent or guardian will not be told the pregnancy test result 342 without the participant's permission, but if the study physician believes that 343 the pregnancy may cause serious health problems, they may need to tell the 344 parent or guardian the test results. Patients with a positive urine drug screen 345 that is not due to prescribed medications are ineligible for study 346 participation. The study physician will ask if the results can be shared with 347 the parent or guardian. This information will be kept confidential if the 348

It is made available under a CC-BY 4.0 International license .

participant chooses not to share the drug test results with the parent or 349 guardian. The result from the urine drug test will not become part of the 350 medical record, but the results will remain in the study record. 351 Additional screening assessments (Table 2) include the 352 Transcranial Magnetic Stimulation Safety Screen [69], Antidepressant 353 Treatment History Form [70], Pubertal Development Scale [71], Mini-354 International Neuropsychiatric Interview for Children and Adolescents 355 (MINI-KID) for participants aged 12 to 17 years [72] or the Mini-356 International Neuropsychiatric Interview for participants aged 18 years [73], 357 Young Mania Rating Scale [74], Children's Depression Rating Scale 358 Revised (CDRS-R) [75], C-SSRS [68], Beck Depression Interview-II [76], 359 360 and Clinical Global Impressions-Severity Scale [77]. Also discussed and noted at the screening visit are concurrent use of medications, adverse events 361 362 (AEs), serious AEs (SAEs), the case report form (CRF), and concurrent psychotherapy. The screening visit can occur on the same day or across 2 363 consecutive days depending on participant preference. 364 After eligibility is confirmed, additional assessments will be 365 completed at a subsequent visit. These assessments include the NIH (US 366 367 National Institutes of Health) Toolbox Cognition Battery [78] and a pretreatment expectations survey. The Young Mania Rating Scale, CDRS-R, 368 C-SSRS, and Beck Depression Interview-II will be repeated, and concurrent 369 use of medications, concurrent psychotherapy, and CRFs will be reviewed. 370 During the intervention period, AEs and SAEs will be recorded. TMS 371 372 neurophysiological data also will be collected.

After acceptance into the trial, each participant is randomly
assigned to either the active aTBS group or sham aTBS, as described in the

It is made available under a CC-BY 4.0 International license .

Randomization and Blinding section. Coil localization (Beam F3 method)
and MT procedures are completed [79]. The participant will complete day 1
of aTBS as assigned (either 3 active sequential bilateral TBS sessions or 3
bilateral sham sessions). Treatment continues for 9 more days if tolerated. *Sample Size*

- Based on prior experience, it is anticipated that 200 patients will 380 be screened and 100 will be enrolled to reach the target sample size of 80 381 needed to complete this pilot study. The sample size for the primary 382 outcome (suicidal ideation over 10 days of sequential bilateral aTBS 383 treatment) was estimated by incorporating a repeated-measures design with 384 assumptions about potential participants (eg, effect size, odds ratio [OR]). 385 386 These assumptions were based on a 2018 study of the effect of bilateral repetitive TMS vs sham stimulation on suicidal ideation in adult patients 387 with treatment-resistant MDD [31]. The results from the a priori sample size 388 estimation and power analysis suggested that a sample size of 35 participants 389 per group (N=70) would achieve 80% power at a .05 α level (2-tailed) [31]. 390 The aim is to detect an overall OR of 2.85 for the primary outcome of less 391 suicidal ideation with sequential bilateral aTBS vs sham stimulation in a 2-392 393 group (between-participants) randomized design. The posited OR is based on 10 (within-participants) repeated measurements of severity of suicidal 394 ideation on the CSSR-S subscale, when the proportion (incident rate) of 395 suicidal ideation from the sham group at the end of the 10-day trial meets or 396 exceeds 0.50 and the assumed within-participant correlation between 397 observations (suicide ideation) for the same participant is 0.50 or less. (A 398 correlation of 0.50 was based on guidance from our preliminary study of 399
- 400 TMS [14].) The posited OR of 2.85 for the current application is slightly

It is made available under a CC-BY 4.0 International license .

401 more conservative than what was reported in a study by Weissman et al [31]
402 of effects of bilateral TMS vs sham stimulation on suicidal ideation in adult
403 patients with treatment-resistant MDD (OR=3.03).

The dropout rate is estimated to be 10%, an approximation based on treatment discontinuation results from our previous repetitive TMS studies [14,80,81]. Thus, 80 participants will be enrolled to allow for this expected rate of attrition with the intent of capturing evaluable data for 70 participants. PASS (Power Analysis and Sample Size) 2019 software version 14.0.15 (NCSS) was used to perform the sample size and power analysis.

To definitively evaluate the effect of sequential bilateral aTBS 410 treatment on suicidal ideation in adolescents, we may require a sample size 411 412 larger than 70. The treatment effect of sequential bilateral aTBS has not been previously studied in adolescents with suicidal depression, and we have no 413 previous findings from an adolescent population to guide effect size 414 selection for the present effort. The selection of 70 participants was, in part, 415 resource driven. The sample size is designed to detect a moderate effect and 416 to establish a proof of concept so that the research can expand to a 417 subsequent, larger-scale multicenter study. Nevertheless, the current pilot 418 419 study permits an evaluation of whether receiving sequential bilateral aTBS shows initial evidence of improving suicidal ideation in depressed 420 adolescents. 421

422 Recruitment

Recruitment began April 4, 2022, after the protocol v2.0 was
finalized and approved by the Data and Safety Monitoring Board (DSMB)
November 10, 2021. The estimated completion date of the study is
December 31, 2026. Adolescent participants are being recruited through the

It is made available under a CC-BY 4.0 International license .

Mayo Clinic Depression Center and Division of Child and Adolescent 427 Psychiatry in Rochester, Minnesota. Recruitment is occurring through 428 outpatient clinics, an 18-bed child and adolescent inpatient psychiatry unit, 429 and Mayo Clinic Emergency Medicine Department in Rochester. Mayo 430 Clinic Health System clinics throughout Minnesota and Wisconsin provide 431 additional recruitment environments. Ongoing and future outreach efforts 432 also involve local community and private treatment facilities in Rochester, 433 St Paul, and Minneapolis in Minnesota. The PI (P.E.C.) has prior and 434 planned collaborations with the Rochester Public School District, Rochester, 435 Minnesota, including consultation with the school board. With appropriate 436 approvals, recruitment flyers will be disseminated to the parents of all 437 adolescents attending Rochester public schools. 438

During inpatient hospitalizations, outpatient visits, and emergency 439 medicine department evaluations, a treatment team member will inform the 440 research team and attending physician of a patient's potential interest. The 441 attending physician will review the request and determine whether a 442 discussion of research participation is appropriate. The PI or another 443 research team member will be contacted to speak to the patient and family 444 regarding participation. If the patient and family are interested, the research 445 team will initiate the informed consent process. 446

The research team will discuss the study during staff meetings at internal clinical services and external facilities. External efforts will be tailored to foster community education regarding depression and suicidality in adolescents while establishing referral patterns. Flyers approved by the Mayo Clinic Institutional Review Board (IRB) will be posted in facilities to advertise the study. The research team will participate in local and national

It is made available under a CC-BY 4.0 International license .

events such as Suicide Awareness Day, National Depression Day, and
National Mental Health Day to facilitate community engagement and
participant recruitment. The PI will continue to access and collaborate with
relevant offices in the Mayo Clinic Center for Clinical and Translational
Science such as the Office of Community Engagement. These collaborations
provide local speaking opportunities.

459 Randomization and Blinding

Randomization will occur for each participant when that person 460 meets all inclusion criteria, does not have any exclusions, and has 461 satisfactorily completed all prestudy procedures. The study biostatistician 462 (P.A.N.) generated a randomization schedule using a random number 463 program on software (SAS via PROC PLAN, SAS Institute Inc). 464 Participants will be randomly assigned in a 1:1 ratio to receive 1 of the 2 465 treatment regimens (either 3 daily sequential bilateral aTBS sessions in the 466 active arm or 3 daily sham sessions in the control arm) for 10 days. 467

The use of active and placebo (sham) coils facilitates blinding of 468 the operator and participants receiving aTBS or sham treatments. A 469 pretreament and posttreatment expectancy and experience form will ask 470 participants and parents to make a guess regarding their treatment arm 471 (active or sham). Blinded study team members will also be asked to guess 472 treatment assignments for each participant. The study team members 473 completing clinical rating scales will not be allowed in the treatment suite 474 during TBS treatment sessions and will be blinded to treatment assignment. 475 In the event of a device-related serious adverse effect, the PI will 476 carefully assess whether breaking the blinding will critically affect how a 477 participant is treated in response to the adverse effect and whether this 478

knowledge outweighs the implications to the scientific soundness of the
study. This decision will be reviewed and approved by the study medical
monitor. For most serious adverse effects, treatment would be discontinued,
and symptoms would be treated regardless of the knowledge of whether the
treatment received was active or sham.

484 **Data Collection and Management**

The primary acute outcome measure is the score on the C-SSRS 485 of the 5-point severity of ideation subscale, with 1 indicating wish to be 486 dead; 2, nonspecific active suicidal thoughts; 3, suicidal thoughts with any 487 methods (no plan) without intent; 4, active suicidal ideation with some 488 suicidal intent without a plan; and 5, active suicidal ideation with suicidal 489 490 intent and a plan [68]. Another C-SSRS subscale that will be used is the intensity of ideation subscale (composed of frequency, duration, 491 controllability, deterrents, and reasons for ideation) [68]. The C-SSRS has 492 been validated for assessing suicidal ideation and behavior in adolescents 493 and adults, with good predictive validity for death by suicide [68] (Table 2). 494 The other study instruments are mentioned in the Participant Timeline 495 section and Table 2. 496

497 Study retention is expected to be high for this study for multiple reasons. During the treatment phase of the study, participants will have 498 499 frequent contact with the study team's child and adolescent psychiatrist (10 daily visits). Both the participants and their parent or legal guardian will be 500 told to contact their study doctor if the participant has any major mood or 501 behavioral changes including suicidal ideation. Ongoing monitoring for 502 worsening of depression and emergence of suicidal ideation and suicidal 503 behaviors will be performed with the CDRS-R, C-SSRS, and Clinical Global 504

It is made available under a CC-BY 4.0 International license .

Impression-Severity Scale [68,77,82]. Additionally, the scheduling 505 flexibility (including weekends) and the TBS dosing parameters (more 506 tolerable treatment intensity) should be highly effective in retaining 507 adolescent participants in this study. Nonadherence to the assigned treatment 508 regimen is defined as missing 2 or more treatment days, or missing more 509 than 20% of the total number of treatment sessions (ie, 6 sessions) occurring 510 during the 2 weeks of treatment as outlined in the schedule of events. 511 Outcomes data will be included in the analyses for any participant randomly 512 assigned into the study who received at least 1 exposure (treatment) from the 513 study device. 514 A CRF will be completed for each participant enrolled in the 515 516 clinical study. The investigator-sponsor will review, approve, and sign and date each completed form to show responsibility for ensuring that all clinical 517 518 data entered on the CRF are complete, accurate, and authentic. All study data will be managed as follows: 519 1. Data will be entered into a secure database (REDCap, Vanderbilt 520 521 University). 2. Study data will be reviewed regularly by the PI and the Study 522 Coordinator for the following: 523 a. Inclusion criteria are met. 524 b. Data are transcribed accurately and completely. 525 c. Units of measure are recorded appropriately. 526 3. Details of the study treatments including treatment parameters, such 527 528 as percentage MT for each treatment, will be stored in the device manufacturer's software (MagVenture Research Study System 529

530		software, MagVenture Inc). A daily summary of the treatments will be
531		created and stored in the participant's source document.
532	4.	Case files will be created for each participant where completed visit
533		CRFs will be stored. Any AE-related CRFs will also be stored in the
534		case file.
535	5.	Nonelectronic source documents containing data will be stored in a
536		locked cabinet in a secure office. Only authorized study staff will have
537		access.
538	6.	Electronic data will be stored in a secure database. Only authorized
539		users will have access. All users will have unique identifiers and
540		passwords. Sharing logon information is not permitted.
541	Statis	stical Analysis
542		All statistical analyses will be performed with SAS software
543	versi	on 9.4 (SAS Institute Inc). The level of significance will be set at α =.05
544	(2-tai	led). To address multiple testing where applicable, P values will be
545	adjus	ted by using the false discovery rate [83].
546		Suicidal ideation (as measured by the score of the C-SSRS
547	sever	ity of ideation subscale) over the 10-day sequential bilateral aTBS trial
548	perio	d is the primary ordinal outcome measure (hypothesis 1a). The short-
549	term	change over time (10 days) in suicidal ideation will be compared
550	betwo	een the 2 treatment groups (sequential bilateral aTBS vs sham
551	stimu	lation) by using an ordinal logistic regression model within a
552	gener	ralized estimating equation (GEE) framework. The logistic model will
553	conta	in fixed-effects terms for treatment, time, and treatment \times time
554	intera	action along with baseline C-SSRS severity of ideation subscale as a
555	covai	riate. Age, sex, pubertal status, antidepressant medication status, and

It is made available under a CC-BY 4.0 International license .

depression severity (CDRS-R total as a time-varying covariate) will also be
covariates in the model. Simple treatment group effects will also be assessed
in each study period (10 days or 12 months). (See the sensitivity analysis
section later for a missing not at random [MNAR] mechanism.)

After the treatment period ends, suicidal ideation will be assessed 560 at monthly follow-up visits over a 12-month period (hypothesis 1b). An 561 ordinal logistic regression model within a GEE analysis framework similar 562 to that described for the primary outcome (hypothesis 1a) will be used to 563 estimate suicidal ideation over the 12-month follow-up period. In addition to 564 the covariates specified for the primary outcome, we will also consider 565 including pharmacotherapy and psychotherapeutic intervention received 566 over the follow-up period as additional covariates. 567

Emergency department visits and hospitalization visits related to 568 suicidality will be assessed at monthly follow-up visits over the 12-month 569 follow-up period (hypothesis 1c). A separate Poisson mixed-model analysis 570 will be used to estimate the number of emergency department visits and the 571 number of hospitalization visits for those who received sequential bilateral 572 aTBS and for those who received sham stimulation. The model will contain 573 574 fixed-effects terms for treatment, time, and treatment \times time interaction, with the same covariates identified earlier. Simple treatment group effects 575 will also be assessed in each period. Maximum likelihood estimation, type 3 576 tests of fixed effects, and generalized least-squares means will be used along 577 with the best-fitting covariance structure. The sandwich (robust covariance 578 matrix) estimator will also be considered. The Poisson model will be 579 checked for overdispersion. The Poisson regression will model the logarithm 580 of each outcome as a random variable, and the mean and variance will be 581

It is made available under a CC-BY 4.0 International license .

setimated on the logarithmic scale. Thus, to facilitate interpretation,

583 geometric means will be reported, which will be obtained by exponentiating

the log-scale parameter estimates. Generalized linear mixed-model

585 procedures software (PROC GLIMMIX, SAS/STAT, SAS Institute Inc) will

be used to conduct the Poisson regression for hypothesis 1c and provide a

robust mechanism for handling data that are assumed missing at random.

588 (See the sensitivity analysis section for data that are MNAR.) No subgroup

analyses are planned.

An ordinal logistic regression model will be used to estimate 590 severity of suicidal ideation at baseline from LICI-100 measured with TMS-591 EMG before the intervention (hypothesis 2a). Age, sex, pubertal status, 592 593 antidepressant medication status, and depression severity at baseline (CDRS-R total) will be covariates in the model. The maximum likelihood estimation 594 and type 3 tests of fixed effects will be used along with the Wald χ^2 statistic. 595 Robust standard errors (Huber sandwich estimator) will also be considered. 596 For the ordinal logistic regression, the cumulative probabilities will be 597 modeled over the lower-ordered suicidal ideation scale scores (less suicidal 598 ideation). The adjusted ORs (odds of suicidal ideation from LICI with TMS-599 EMG) and 95% CI will be estimated as part of the model to interpret the 600 relationship between the TMS-EMG biomarker and baseline suicidal 601 ideation. 602

An ordinal logistic regression model within a GEE analysis framework similar to that described for hypothesis 1a will be used to examine the relationship between cortical inhibition (LICI-100 measured with TMS-EMG as a time-varying covariate) and C-SSRS severity of ideation subscale (as the response variable) over the 10-day treatment trial

It is made available under a CC-BY 4.0 International license .

(hypothesis 2b). The parameter estimates (regression coefficients) will be
interpreted from the solution for fixed effects in the GEE analysis. The
adjusted OR (odds of suicidal ideation from cortical inhibition) and 95% CI
will be estimated as part of the GEE model. The same covariates specified
for hypothesis 1a will be in the model for hypothesis 2b.

An ordinal logistic regression model within a GEE analysis 613 framework similar to that described earlier for hypothesis 2b will be used to 614 examine the relationship between cortical inhibition (TMS-EEG markers 615 N45 and N100) and C-SSRS severity of ideation subscale (as the response 616 variable) over the 10-day treatment trial (hypothesis 3). A separate model 617 will be implemented for each measure of TMS-EEG cortical inhibition. The 618 619 same covariates specified for hypothesis 2b will be in the model for hypothesis 3. The parameter estimates (regression coefficients) will be 620 interpreted from the solution for fixed effects in the GEE analysis. The 621 adjusted OR (odds of suicidal ideation from TMS-EEG cortical inhibition) 622 and 95% CI will be estimated as part of the GEE model. 623

624 Sensitivity Analysis to Handle Missing Data

A sensitivity analysis is planned to address incomplete response 625 patterns according to an MNAR mechanism. First, we will follow the 626 outcome-based model of Diggle and Kenward [84] for longitudinal data with 627 nonrandom missingness along with the model-based approach proposed by 628 Carpenter et al [85] for modeling both the treatment response and the 629 missing data process. These models are summarized here. If deemed 630 631 necessary, we will build longitudinal models for the data, which include a model for the dropout (or missing data) process to assess the sensitivity of 632 the results about the dependence between dropout (or missingness) and 633

It is made available under a CC-BY 4.0 International license .

treatment response. Additionally, if deemed necessary, we will consider 634 implementing the semiparametric shared parameter model described by 635 Tsonaka et al [86] to handle nonmonotone nonignorable missingness for 636 mixed-effects models. A pattern-mixture model will also be considered if 637 necessary. The results from such nonrandom dropout/missingness models 638 will then be compared with the results from the proposed standard methods 639 (dropout or missing at random models) to assess the sensitivity of the results 640 to the effect of dropouts (or incomplete response patterns according to an 641 MNAR mechanism). 642

643 Data Monitoring

An National Institute of Mental Health (NIMH)-constituted 644 DSMB is overseeing the study in accordance with the NIMH DSMB charter 645 guidelines [87]. Clinical monitoring will be conducted by the NIMH Clinical 646 Research Education, Support, and Training program. Goals of clinical site 647 monitoring are to ensure that the rights and well-being of participants are 648 protected; that the reported trial data are accurate, complete, and verifiable; 649 and that the conduct of the trial complies with the approved protocol and any 650 amendments, good clinical practice, and applicable regulatory requirements. 651 652 Clinical monitoring includes reviewing the study database and documents including regulatory documents. Monitoring will be conducted throughout 653 the study and involves targeted data verification of key data variables. 654 Details of clinical site monitoring are documented in the clinical monitoring 655 plan. This plan describes who will conduct the monitoring, at what 656 657 frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. Copies of monitoring 658 reports will be provided to the PI and to the NIMH DSMB liaison. 659

It is made available under a CC-BY 4.0 International license .

660 An individualized quality management plan was developed to 661 describe the clinical site's quality management in addition to the site's 662 assurance and quality control measures already in place. The site staff will 663 perform internal quality management of study conduct, data collection, and 664 data documentation.

665 Interim Analyses and Study-Stopping Rules

No interim analyses are planned. Study-stopping rules were 666 developed in collaboration with the FDA and NIMH DSMB to ensure that 667 participants are not exposed to risks across the study and that any potential 668 risks are evaluated. These stopping rules apply to the 2-week period when 669 participants are receiving the study intervention (active or sham sequential 670 bilateral aTBS) but do not apply to the naturalistic 1-year follow-up portion 671 of the study. No study-stopping rules were predetermined for events that 672 673 take place during the follow-up period because suicide attempts and psychiatric hospitalizations are expected to be common events. AEs 674 occurring during the follow-up period will be tracked. The study team will 675 evaluate the expectedness and relatedness of these events; the IRB, DSMB, 676 and FDA will provide oversight of these determinations. AEs and SAEs will 677 678 be reported in the data reports and reviewed by the DSMB. The following 679 study-stopping rules apply:

- Two participants who experience a seizure.
- One or more participants who experience status epilepticus.
- One or more participants who attempt or die by suicide.
- Two or more SAEs related to the study intervention and occurring
 within the 2-week treatment period for 1 or more participants.

It is made available under a CC-BY 4.0 International license .

If these study-stopping rules are met, enrollment of new participants will cease, but all study activities will continue for enrolled participants. The PI will consult with the DSMB and the FDA within 10 business days of initial notice that study-stopping rules were met.

689 AE Reporting and Harm

All AEs occurring during the study, including those not meeting 690 the criteria of an unanticipated adverse device effect (UADE), will be 691 recorded on the appropriate CRF. Expected clinical AEs and anticipated 692 adverse device effects include pain or discomfort under the treatment coil; 693 eye, facial, or skin pain; facial numbress or facial muscle twitching; 694 toothache; blurred vision; seizures; cardiogenic syncope; sedation; and 695 696 worsening mood symptoms. UADEs will be reported to the DSMB, FDA, and IRB immediately. Records of these events will be maintained, and 697 reports will be submitted to the FDA and IRB according to the regulatory 698 requirements. Expected clinical AEs and nonserious clinical AEs will be 699 reported annually. 700

The study follow-up period is defined as 12 months after the last 701 administration of study treatment. All AEs occurring during the study 702 treatment period will be recorded as required. All observed or volunteered 703 adverse effects (serious or nonserious) and abnormal test findings will be 704 recorded in the participant's case history regardless of the treatment group or 705 a suspected causal relationship to the investigational device or, if applicable, 706 707 to other study treatment or diagnostic products. For all adverse effects, sufficient information will be pursued and obtained regarding permit, an 708 adequate determination of the outcome, and an assessment of the causal 709 relationship between the adverse effect and the investigational device or 710

It is made available under a CC-BY 4.0 International license .

other study treatment or diagnostic product. The clinical course of each
event will be followed up, as required, until resolution or stabilization or
until the study treatment or participation is determined to not be the probable
cause. SAEs that are still ongoing at the end of the study will be followed up
to determine the final outcome. Any SAE that occurs after the study period
and is considered to be at least possibly related to the study treatment or
study participation will be recorded and reported immediately.

The sponsor-investigator will promptly review documented 718 adverse effects and abnormal test findings to determine the following: 1) 719 whether the abnormal test finding should be classified as an adverse effect; 720 2) whether there is a reasonable possibility that the adverse effect was 721 722 caused by the investigational device or other study treatments; and 3) whether the adverse effect meets the criteria for a serious adverse effect. If 723 the sponsor-investigator's final determination of causality is "unknown and 724 of questionable relationship to the investigational device or other study 725 treatments," the adverse effect will be classified as associated with the use of 726 the investigational device or other study treatments for reporting purposes. If 727 the sponsor-investigator's final determination of causality is "unknown but 728 not related to the investigational device or other study treatments," this 729 730 determination and the rationale for the determination will be documented in the respective participant's case history. 731

The sponsor-investigator will promptly review documented UADEs (FDA Form 3500A) and will report the results from the evaluation to the FDA and DSMB within 10 workdays and to the Mayo Clinic IRB within 5 workdays of initial notice of the effect. Thereafter, the sponsor-

It is made available under a CC-BY 4.0 International license .

736 investigator will submit additional reports concerning the effect as

737 requested.

The sponsor-investigator will permit study-related monitoring, 738 audits, and inspections by the IRB, the monitors, and government regulatory 739 agencies of all study-related documents (eg, source documents, regulatory 740 documents, data collection instruments, study data). The sponsor-741 investigator will ensure the capability for inspections of applicable study-742 related facilities (eg, pharmacy, diagnostic laboratory). Participation as a 743 sponsor-investigator in this study implies acceptance of potential inspection 744 by government regulatory authorities and applicable compliance offices. 745

746 Ethics and Dissemination

747 Informed Consent

Prospective participants will be assured that participation is 748 voluntary. All participants for this study will receive a consent/assent form 749 describing this study and providing sufficient information for participants 750 and their parents or legal guardian to make an informed decision about 751 whether to participate. Formal consent must be obtained by using the 752 approved IRB consent form before a participant undergoes any study 753 754 procedure. The consent form must be signed and dated by the participant or the participant's legally authorized representative, and by the study team 755 member obtaining the informed consent. 756

757 *Confidentiality*

Information including clinical information about study
participants will be kept confidential and managed according to the
requirements of the Health Insurance Portability and Accountability Act of
1996 (HIPAA). Those regulations require a signed authorization by each

It is made available under a CC-BY 4.0 International license .

study participant informing the participant of the following: what protected 762 health information (PHI) [12] will be collected from participants, who will 763 have access to that information and why, who will use or disclose that 764 information, and the rights of a participant to revoke their authorization to 765 use their PHI. If a participant revokes authorization to collect or use PHI, the 766 investigator, by regulation, retains the ability to use all information collected 767 before the revocation of participant authorization. For participants who have 768 revoked authorization to collect or use PHI, attempts will be made to obtain 769 permission to collect at least vital status (long-term survival status that the 770 participant is alive) at the end of the originally scheduled study period. 771

Participant confidentiality and privacy are strictly held in trust by 772 773 the participating investigators, their staff, and the sponsor. Therefore, the study documentation, data, and all other information generated will be held 774 in strict confidence. No information concerning either the study or the data 775 will be released to any unauthorized third party without prior written 776 approval of the sponsor. All research activities will be conducted in as 777 private a setting as possible. Potential participants will have the opportunity 778 to discuss study participation without their parent or guardian present. The 779 780 study monitor, other authorized representatives of the sponsor, and representatives of the NIH, the FDA, and the Mayo Clinic IRB may inspect 781 all documents and records required to be maintained by the investigator, 782 including but not limited to medical records. Study participants' contact 783 information will be securely stored for internal use during the study. At the 784 end of the study, all records will continue to be kept in a secure location for 785 as long as dictated by the reviewing IRB, institutional policies, FDA 786

It is made available under a CC-BY 4.0 International license .

investigational device exemption (IDE) record requirements, and sponsor
requirements. We are not planning to collect biological specimens.

To further protect the privacy of study participants, the NIH will 789 issue a Certificate of Confidentiality. This certificate protects identifiable 790 research information from forced disclosure. It allows the investigator and 791 others who have access to research records to refuse to disclose identifying 792 information on research participation in any civil, criminal, administrative, 793 legislative, or other proceeding, whether at the federal, state, or local level. 794 By protecting researchers and institutions from being compelled to disclose 795 information that would identify research participants, Certificates of 796 Confidentiality help achieve the research objectives and promote 797 798 participation in studies by helping assure confidentiality and privacy to participants. 799

800 Dissemination

The PI/sponsor holds the primary responsibility for publications of results from the proposed study. The PI/sponsor and study team will present findings at national and international conferences and will publish findings in peer-reviewed journals. Results will be posted to ClinicalTrials.gov within 12 months of final data collection for the primary outcomes.

807

Discussion

This is the first known randomized controlled trial to examine sequential bilateral aTBS in depressed adolescents with suicidal ideation. The study addresses 2 NIMH Strategic Research Strategies: 3.2, "Develop ways to tailor existing and new interventions to optimize outcomes," and 3.3, "Test interventions for effectiveness in community practice settings"

813	[88,89]. If this aTBS treatment protocol and the proposed panel of
814	biomarkers are shown to be safe and effective, they can be rapidly
815	implemented into clinical practice. This novel approach may facilitate a
816	critical paradigm shift toward brain-based approaches for assessing and
817	treating suicidal ideation in adolescents with MDD.
818	Supplementary Information
819	The online version contains supplementary material (Appendix 1.
820	Standard Protocol Items: Recommendations for Interventional Trials
821	[SPIRIT] 2013 Checklist [additional file 1.doc]; Appendix 2. Study
822	Administrative Information [additional file 2.doc]. Appendix 3. Sample
823	Consent Forms [additional file 3.pdf and additional file 4.pdf] [Used with
824	permission of Mayo Foundation for Medical Education and Research.].
825	Declarations
826	Ethics Approval and Consent to Participate
827	This study is to be conducted according to US government
828	regulations and institutional research policies and procedures. This protocol
829	was submitted, and any amendments will be submitted, to a properly
830	constituted local institutional review board (IRB), the Mayo Clinic IRB, in
831	agreement with local legal prescriptions, for formal approval of the study.
832	The IRB approved this study (#20-009630). All participants or their parents
833	or legal guardian will be asked to sign an informed consent form as
834	described in the article.
835	Consent for Publication
836	Not applicable.

It is made available under a CC-BY 4.0 International license .

837 Availability of Data

Because the study is funded by the National Institute of Mental 838 Health (NIMH), data sharing through the NIMH Data Archive (NDA) is 839 required. The NDA is a large database in which deidentified study data from 840 many NIMH studies are stored and managed. Any researcher who requests 841 access to the deidentified data of the NDA is bound to adhere to strict data 842 safety practices and to avoid any attempts at deidentification. The 843 investigators' intention to submit deidentified participant data to the NDA is 844 stated in the consent and assent documents, and participants or guardians are 845 able to opt out of this data sharing at any time. Opting out of NDA data 846 sharing does not in any way affect trial eligibility. 847

848 Competing Interests

Dr Croarkin has received research grant support from Neuronetics 849 Inc, NeoSync Inc, and Pfizer Inc. He has received in-kind support 850 (equipment, supplies, and genotyping) for research studies from Assurex 851 Health Inc, Neuronetics Inc, and MagVenture Inc. He has consulted for 852 Engrail Therapeutics Inc, Myriad Neuroscience, Procter & Gamble, and 853 Sunovion. Dr Vande Voort has received in-kind support (supplies and 854 genotyping) from Assurex Health Inc. The other authors declare that they 855 have no competing interests. 856

857 Funding

This project is supported by Grant Number 1 R01 MH124655-01 from the NIMH, National Institutes of Health (NIH), and by Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS). The content of this protocol and publication is solely the

It is made available under a CC-BY 4.0 International license .

responsibility of the authors and does not necessarily represent the official

- views of the NIH.
- 864 Authors' Contributions
- P.E.C. is the principal investigator, conceived the study concept,
- and spearheaded protocol development. P.A.N., M.J.Z., J.L.V., J.M.L., J.S.,
- and P.E.C. designed the study aims, hypotheses, and statistical analyses.
- 868 D.Y., C.O., and J.F.G. drafted the protocol, provided additional intellectual
- 869 input, and made substantial revisions. All authors read and approved the
- 870 final manuscript.
- 871 Authors' Information
- 872 See title page.

873

874		References
875	1.	Fazel S, Runeson B. Suicide. N Engl J Med. 2020;382(3):266-74.
876	2.	Kann L, McManus T, Harris WA, Shanklin SL, Flint KH, Queen B, et
877		al. Youth Risk Behavior Surveillance - United States, 2017. MMWR
878		Surveill Summ. 2018;67(8):1-114.
879	3.	World Health Organization. Preventing suicide: a global imperative.
880		Geneva: World Health Organization; 2014. Available from:
881		https://www.who.int/publications/i/item/9789241564779.
882	4.	Miron O, Yu KH, Wilf-Miron R, Kohane IS. Suicide Rates Among
883		Adolescents and Young Adults in the United States, 2000-2017.
884		JAMA. 2019;321(23):2362-4.
885	5.	Olfson M, Blanco C, Wall M, Liu SM, Saha TD, Pickering RP, et al.
886		National Trends in Suicide Attempts Among Adults in the United
887		States. JAMA Psychiatry. 2017;74(11):1095-103.
888	6.	Copeland WE, Goldston DB, Costello EJ. Adult Associations of
889		Childhood Suicidal Thoughts and Behaviors: A Prospective,
890		Longitudinal Analysis. J Am Acad Child Adolesc Psychiatry.
891		2017;56(11):958-65 e4.
892	7.	Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT,
893		et al. The Treatment of Adolescent Suicide Attempters study (TASA):
894		predictors of suicidal events in an open treatment trial. J Am Acad
895		Child Adolesc Psychiatry. 2009;48(10):987-96.
896	8.	Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E,
897		Sarchiapone M, et al. Suicide prevention strategies revisited: 10-year
898		systematic review. Lancet Psychiatry. 2016;3(7):646-59.

899	9.	Bennett K, Rhodes AE, Duda S, Cheung AH, Manassis K, Links P, et
900		al. A Youth Suicide Prevention Plan for Canada: A Systematic
901		Review of Reviews. Can J Psychiatry. 2015;60(6):245-57.
902	10.	Franklin JC, Ribeiro JD, Fox KR, Bentley KH, Kleiman EM, Huang
903		X, et al. Risk factors for suicidal thoughts and behaviors: A meta-
904		analysis of 50 years of research. Psychol Bull. 2017;143(2):187-232.
905	11.	Gordon JA, Frost Bellgowan JA, Lawhorn C, Scheinert RB.
906		Challenges and Opportunities in Psychiatric Neuroscience. Cold
907		Spring Harb Symp Quant Biol. 2018;83:1-8.
908	12.	Kapur S, Phillips AG, Insel TR. Why has it taken so long for
909		biological psychiatry to develop clinical tests and what to do about it?
910		Mol Psychiatry. 2012;17(12):1174-9.
911	13.	Perlis RH. Translating biomarkers to clinical practice. Mol Psychiatry.
912		2011;16(11):1076-87.
913	14.	Croarkin PE, Nakonezny PA, Deng ZD, Romanowicz M, Voort JLV,
914		Camsari DD, et al. High-frequency repetitive TMS for suicidal
915		ideation in adolescents with depression. J Affect Disord.
916		2018;239:282-90.
917	15.	Bastiampillai T, Sharfstein SS, Allison S. Increasing the Use of
918		Lithium and Clozapine in US Suicide Prevention. JAMA Psychiatry.
919		2017;74(4):423.
920	16.	Daskalakis ZJ, Farzan F, Barr MS, Rusjan PM, Favalli G, Levinson
921		AJ, et al. Evaluating the relationship between long interval cortical
922		inhibition, working memory and gamma band activity in the
923		dorsolateral prefrontal cortex. Clin EEG Neurosci. 2008;39(3):150-5.

924	17.	Croarkin PE.	Levinson AJ.	Daskalakis ZJ.	Evidence for	GABAergic
/ .	- / •					0112110171

- 925 inhibitory deficits in major depressive disorder. Neurosci Biobehav
 926 Rev. 2011;35(3):818-25.
- 18. Krnjevic K. Glutamate and gamma-aminobutyric acid in brain.
 Nature. 1970;228(5267):119-24.
- 929 19. Schmaal L, van Harmelen AL, Chatzi V, Lippard ETC, Toenders YJ,
 930 Averill LA, et al. Imaging suicidal thoughts and behaviors: a
- 931 comprehensive review of 2 decades of neuroimaging studies. Mol
 932 Psychiatry. 2020;25(2):408-27.
- 20. Chang BP, Franklin JC, Ribeiro JD, Fox KR, Bentley KH, Kleiman
 EM, et al. Biological risk factors for suicidal behaviors: a metaanalysis. Transl Psychiatry. 2016;6(9):e887.
- 936 21. Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH,
- 937 Sublette ME, et al. Toward a biosignature for suicide. Am J
 938 Psychiatry. 2014;171(12):1259-77.
- 939 22. Gabbay V, Bradley KA, Mao X, Ostrover R, Kang G, Shungu DC.
- Anterior cingulate cortex gamma-aminobutyric acid deficits in youth
 with depression. Transl Psychiatry. 2017;7(8):e1216.
- Gabbay V, Mao X, Klein RG, Ely BA, Babb JS, Panzer AM, et al.
 Anterior cingulate cortex gamma-aminobutyric acid in depressed
 adolescents: relationship to anhedonia. Arch Gen Psychiatry.
- 945 2012;69(2):139-49.
- 24. Lewis CP, Nakonezny PA, Ameis SH, Vande Voort JL, Husain MM,
- 947 Emslie GJ, et al. Cortical inhibitory and excitatory correlates of
- 948 depression severity in children and adolescents. J Affect Disord.
- 949 2016;190:566-75.

950	25.	Lewis CP, Nakonezny PA, Blacker CJ, Vande Voort JL, Port JD,
951		Worrell GA, et al. Cortical inhibitory markers of lifetime suicidal
952		behavior in depressed adolescents. Neuropsychopharmacology.
953		2018;43(9):1822-31.
954	26.	King JD, Horton SE, Hughes JL, Eaddy M, Kennard BD, Emslie GJ,
955		et al. The Interpersonal-Psychological Theory of Suicide in
956		Adolescents: A Preliminary Report of Changes Following Treatment.
957		Suicide Life Threat Behav. 2018;48(3):294-304.
958	27.	Kotak VC, Mirallave A, Mowery TM, Sanes DH. GABAergic
959		inhibition gates excitatory LTP in perirhinal cortex. Hippocampus.
960		2017;27(12):1217-23.
961	28.	Levitt JG, Kalender G, O'Neill J, Diaz JP, Cook IA, Ginder N, et al.
962		Dorsolateral prefrontal gamma-aminobutyric acid in patients with
963		treatment-resistant depression after transcranial magnetic stimulation
964		measured with magnetic resonance spectroscopy. J Psychiatry
965		Neurosci. 2019;44(6):386-94.
966	29.	Li CT, Huang YZ, Bai YM, Tsai SJ, Su TP, Cheng CM. Critical role
967		of glutamatergic and GABAergic neurotransmission in the central
968		mechanisms of theta-burst stimulation. Hum Brain Mapp.
969		2019;40(6):2001-9.
970	30.	George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes
971		KT, et al. A two-site pilot randomized 3 day trial of high dose left
972		prefrontal repetitive transcranial magnetic stimulation (rTMS) for
973		suicidal inpatients. Brain Stimul. 2014;7(3):421-31.
974	31.	Weissman CR, Blumberger DM, Brown PE, Isserles M, Rajji TK,
975		Downar J, et al. Bilateral Repetitive Transcranial Magnetic

976		Stimulation Decreases Suicidal Ideation in Depression. J Clin
977		Psychiatry. 2018;79(3).
978	32.	Stagg CJ, Wylezinska M, Matthews PM, Johansen-Berg H, Jezzard P,
979		Rothwell JC, et al. Neurochemical effects of theta burst stimulation as
980		assessed by magnetic resonance spectroscopy. J Neurophysiol.
981		2009;101(6):2872-7.
982	33.	McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M,
983		Taylor SF, et al. Consensus Recommendations for the Clinical
984		Application of Repetitive Transcranial Magnetic Stimulation (rTMS)
985		in the Treatment of Depression. J Clin Psychiatry. 2018;79(1).
986	34.	Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A,
987		Wirecki TS. The Clinical TMS Society Consensus Review and
988		Treatment Recommendations for TMS Therapy for Major Depressive
989		Disorder. Brain Stimul. 2016;9(3):336-46.
990	35.	Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y,
991		Giacobbe P, et al. Effectiveness of theta burst versus high-frequency
992		repetitive transcranial magnetic stimulation in patients with
993		depression (THREE-D): a randomised non-inferiority trial. Lancet.
994		2018;391(10131):1683-92.
995	36.	Fitzgerald PB, Chen L, Richardson K, Daskalakis ZJ, Hoy KE. A pilot
996		investigation of an intensive theta burst stimulation protocol for
997		patients with treatment resistant depression. Brain Stimul.
998		2020;13(1):137-44.
999	37.	Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta
1000		burst stimulation of the human motor cortex. Neuron. 2005;45(2):201-
1001		6.

1002	38.	Mott MC.	Gordon JA.	Koroshetz WJ	. The NIH BRAIN Initiative:

- Advancing neurotechnologies, integrating disciplines. PLoS Biol.
 2018;16(11):e3000066.
- 1005 39. Seewoo BJ, Hennessy LA, Feindel KW, Etherington SJ, Croarkin PE,
- 1006 Rodger J. Validation of Chronic Restraint Stress Model in Young
- 1007Adult Rats for the Study of Depression Using Longitudinal
- 1008 Multimodal MR Imaging. eNeuro. 2020;7(4).
- 1009 40. Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH,
- 1010 Duvio D, et al. High-dose spaced theta-burst TMS as a rapid-acting 1011 antidepressant in highly refractory depression. Brain.
- 1012 2018;141(3):e18.
- 1013 41. Dhami P, Knyahnytska Y, Atluri S, Lee J, Courtney DB, Croarkin PE,
 1014 et al. Feasibility and clinical effects of theta burst stimulation in youth
 1015 with major depressive disorders: An open-label trial. J Affect Disord.
 1016 2019;258:66-73.
- Hong YH, Wu SW, Pedapati EV, Horn PS, Huddleston DA, Laue CS,
 et al. Safety and tolerability of theta burst stimulation vs. single and
 paired pulse transcranial magnetic stimulation: a comparative study of
 165 and listrice bioster Front II, an Neuropei 2015 0.20
- 1020 165 pediatric subjects. Front Hum Neurosci. 2015;9:29.
- 1021 43. Chung SW, Lewis BP, Rogasch NC, Saeki T, Thomson RH, Hoy KE,
- 1022 et al. Demonstration of short-term plasticity in the dorsolateral
- 1023 prefrontal cortex with theta burst stimulation: A TMS-EEG study.
- 1024 Clin Neurophysiol. 2017;128(7):1117-26.
- 1025 44. Gong N, Li Y, Cai GQ, Niu RF, Fang Q, Wu K, et al. GABA
- 1026 transporter-1 activity modulates hippocampal theta oscillation and

1027		theta burst stimulation-induced long-term potentiation. J Neurosci.
1028		2009;29(50):15836-45.
1029	45.	Feng YW, Huang YQ, Yan Y, Li G, He XF, Liang FY, et al. Phasic
1030		GABA signaling mediates the protective effects of cTBS against
1031		cerebral ischemia in mice. Neurosci Lett. 2020;715:134611.
1032	46.	Li CT, Chen MH, Juan CH, Huang HH, Chen LF, Hsieh JC, et al.
1033		Efficacy of prefrontal theta-burst stimulation in refractory depression:
1034		a randomized sham-controlled study. Brain. 2014;137(Pt 7):2088-98.
1035	47.	Kimbrell TA, Little JT, Dunn RT, Frye MA, Greenberg BD,
1036		Wassermann EM, et al. Frequency dependence of antidepressant
1037		response to left prefrontal repetitive transcranial magnetic stimulation
1038		(rTMS) as a function of baseline cerebral glucose metabolism. Biol
1039		Psychiatry. 1999;46(12):1603-13.
1040	48.	Teneback CC, Nahas Z, Speer AM, Molloy M, Stallings LE, Spicer
1041		KM, et al. Changes in prefrontal cortex and paralimbic activity in
1042		depression following two weeks of daily left prefrontal TMS. J
1043		Neuropsychiatry Clin Neurosci. 1999;11(4):426-35.
1044	49.	Sonmez AI, Camsari DD, Nandakumar AL, Voort JLV, Kung S,
1045		Lewis CP, et al. Accelerated TMS for Depression: A systematic
1046		review and meta-analysis. Psychiatry Res. 2019;273:770-81.
1047	50.	Abujadi C, Croarkin PE, Bellini BB, Brentani H, Marcolin MA.
1048		Intermittent theta-burst transcranial magnetic stimulation for autism
1049		spectrum disorder: an open-label pilot study. Braz J Psychiatry.
1050		2018;40(3):309-11.
1051	51.	Croarkin PE, Nakonezny PA, Husain MM, Melton T, Buyukdura JS,
1052		Kennard BD, et al. Evidence for increased glutamatergic cortical

1053		facilitation in children and adolescents with major depressive
1054		disorder. JAMA Psychiatry. 2013;70(3):291-9.
1055	52.	Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M,
1056		Daskalakis ZJ. Evidence of cortical inhibitory deficits in major
1057		depressive disorder. Biol Psychiatry. 2010;67(5):458-64.
1058	53.	Ziemann U, Reis J, Schwenkreis P, Rosanova M, Strafella A, Badawy
1059		R, et al. TMS and drugs revisited 2014. Clin Neurophysiol.
1060		2015;126(10):1847-68.
1061	54.	Ziemann U. Pharmacology of TMS. Suppl Clin Neurophysiol.
1062		2003;56:226-31.
1063	55.	Ziemann U. TMS and drugs. Clin Neurophysiol. 2004;115(8):1717-
1064		29.
1065	56.	Belardinelli P, Biabani M, Blumberger DM, Bortoletto M, Casarotto
1066		S, David O, et al. Reproducibility in TMS-EEG studies: A call for
1067		data sharing, standard procedures and effective experimental control.
1068		Brain Stimul. 2019;12(3):787-90.
1069	57.	Conde V, Tomasevic L, Akopian I, Stanek K, Saturnino GB,
1070		Thielscher A, et al. The non-transcranial TMS-evoked potential is an
1071		inherent source of ambiguity in TMS-EEG studies. Neuroimage.
1072		2019;185:300-12.
1073	58.	Siebner HR, Conde V, Tomasevic L, Thielscher A, Bergmann TO.
1074		Distilling the essence of TMS-evoked EEG potentials (TEPs): A call
1075		for securing mechanistic specificity and experimental rigor. Brain
1076		Stimul. 2019;12(4):1051-4.

1077	59.	Tremblay S, Rogasch NC, Premoli I, Blumberger DM, Casarotto S,
1078		Chen R, et al. Clinical utility and prospective of TMS-EEG. Clin
1079		Neurophysiol. 2019;130(5):802-44.
1080	60.	Voineskos D, Blumberger DM, Zomorrodi R, Rogasch NC, Farzan F,
1081		Foussias G, et al. Altered Transcranial Magnetic Stimulation-
1082		Electroencephalographic Markers of Inhibition and Excitation in the
1083		Dorsolateral Prefrontal Cortex in Major Depressive Disorder. Biol
1084		Psychiatry. 2019;85(6):477-86.
1085	61.	Croarkin PE, Rotenberg A. Pediatric Neuromodulation Comes of Age.
1086		J Child Adolesc Psychopharmacol. 2016;26(7):578-81.
1087	62.	Croarkin PE, Nakonezny PA, Husain MM, Port JD, Melton T,
1088		Kennard BD, et al. Evidence for pretreatment LICI deficits among
1089		depressed children and adolescents with nonresponse to fluoxetine.
1090		Brain Stimul. 2014;7(2):243-51.
1091	63.	Doruk Camsari D, Lewis CP, Sonmez AI, Nandakumar AL,
1092		Gresbrink MA, Daskalakis ZJ, et al. Transcranial Magnetic
1093		Stimulation Markers of Antidepressant Treatment in Adolescents
1094		With Major Depressive Disorder. Int J Neuropsychopharmacol.
1095		2019;22(7):435-44.
1096	64.	Lewis CP, Camsari DD, Sonmez AI, Nandakumar AL, Gresbrink
1097		MA, Daskalakis ZJ, et al. Preliminary evidence of an association
1098		between increased cortical inhibition and reduced suicidal ideation in
1099		adolescents treated for major depression. J Affect Disord.
1100		2019;244:21-4.

1101	65.	Grabb MC, Gobburu JVS. Challenges in developing drugs for
1102		pediatric CNS disorders: A focus on psychopharmacology. Prog
1103		Neurobiol. 2017;152:38-57.
1104	66.	Kennard B, Mayes T, King J, Moorehead A, Wolfe K, Hughes J, et al.
1105		The Development and Feasibility Outcomes of a Youth Suicide
1106		Prevention Intensive Outpatient Program. J Adolesc Health.
1107		2019;64(3):362-9.
1108	67.	Kennard BD, Silva SG, Mayes TL, Rohde P, Hughes JL, Vitiello B, et
1109		al. Assessment of safety and long-term outcomes of initial treatment
1110		with placebo in TADS. Am J Psychiatry. 2009;166(3):337-44.
1111	68.	Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo
1112		MA, et al. The Columbia-Suicide Severity Rating Scale: initial
1113		validity and internal consistency findings from three multisite studies
1114		with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-77.
1115	69.	Keel JC, Smith MJ, Wassermann EM. A safety screening
1116		questionnaire for transcranial magnetic stimulation. Clin
1117		Neurophysiol. 2001;112(4):720.
1118	70.	Sackeim HA. The definition and meaning of treatment-resistant
1119		depression. J Clin Psychiatry. 2001;62 Suppl 16:10-7.
1120	71.	Carskadon MA, Acebo C. A self-administered rating scale for
1121		pubertal development. J Adolesc Health. 1993;14(3):190-5.
1122	72.	Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers
1123		JE, et al. Reliability and validity of the Mini International
1124		Neuropsychiatric Interview for Children and Adolescents (MINI-
1125		KID). J Clin Psychiatry. 2010;71(3):313-26.

1126	73.	Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller
1127		E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.):
1128		the development and validation of a structured diagnostic psychiatric
1129		interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl
1130		20:22-33;quiz 4-57.
1131	74.	Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for
1132		mania: reliability, validity and sensitivity. Br J Psychiatry.
1133		1978;133:429-35.
1134	75.	Poznanski EO, Cook SC, Carroll BJ. A depression rating scale for
1135		children. Pediatrics. 1979;64(4):442-50.
1136	76.	Beck AT, Steer RA, Brown GK. Manual for the Beck Depression
1137		Inventory-II. San Antonio (TX): Psychological Corporation; 1996.
1138	77.	Guy W, National Institute of Mental Health (U.S.).
1139		Psychopharmacology Research Branch., Early Clinical Drug
1140		Evaluation Program. Clinical Global Impressions. ECDEU
1141		assessment manual for psychopharmacology. Rev. ed. Rockville, Md.:
1142		U.S. Dept. of Health Education and Welfare Public Health Service
1143		Alcohol Drug Abuse and Mental Health Administration National
1144		Institute of Mental Health Psychopharmacology Research Branch
1145		Division of Extramural Research Programs; 1976. p. 218-22.
1146	78.	Hodes RJ, Insel TR, Landis SC, Research NIHBfN. The NIH toolbox:
1147		setting a standard for biomedical research. Neurology. 2013;80(11
1148		Suppl 3):S1.
1149	79.	Beam W, Borckardt JJ, Reeves ST, George MS. An efficient and
1150		accurate new method for locating the F3 position for prefrontal TMS
1151		applications. Brain Stimul. 2009;2(1):50-4.

1152	80.	Wall CA, Croarkin PE, Maroney-Smith MJ, Haugen LM, Baruth JM,
1153		Frye MA, et al. Magnetic Resonance Imaging-Guided, Open-Label,
1154		High-Frequency Repetitive Transcranial Magnetic Stimulation for
1155		Adolescents with Major Depressive Disorder. J Child Adolesc
1156		Psychopharmacol. 2016;26(7):582-9.
1157	81.	Wall CA, Croarkin PE, Sim LA, Husain MM, Janicak PG, Kozel FA,
1158		et al. Adjunctive use of repetitive transcranial magnetic stimulation in
1159		depressed adolescents: a prospective, open pilot study. J Clin
1160		Psychiatry. 2011;72(9):1263-9.
1161	82.	Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L,
1162		Gibbons R. Preliminary studies of the reliability and validity of the
1163		children's depression rating scale. J Am Acad Child Psychiatry.
1164		1984;23(2):191-7.
1165	83.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A
1166		Practical and Powerful Approach to Multiple Testing. Journal of the
1167		Royal Statistical Society: Series B (Methodological). 1995;57(1):289-
1168		300.
1169	84.	Diggle P, Kenward MG. Informative Drop-Out in Longitudinal Data
1170		Analysis. Journal of the Royal Statistical Society Series C (Applied
1171		Statistics). 1994;43(1):49-93.
1172	85.	Carpenter J, Pocock S, Lamm CJ. Coping with missing data in clinical
1173		trials: a model-based approach applied to asthma trials. Stat Med.
1174		2002;21(8):1043-66.
1175	86.	Tsonaka R, Verbeke G, Lesaffre E. A Semi-Parametric Shared
1176		Parameter Model to Handle Nonmonotone Nonignorable Missingness.
1177		Biometrics. 2009;65(1):81-7.

- 1178 87. National Institute of Mental Health, National Institutes of Health, US
- 1179 Department of Health and Human Services. NIMH Policy Governing
- 1180the Monitoring of Clinical Trials Bethesda (MD): National Institute of
- 1181 Mental Health; 2015 [Available from:
- 1182 <u>https://www.nimh.nih.gov/funding/clinical-research/nimh-policy-</u>
 1183 governing-the-monitoring-of-clinical-trials.
- 1184 88. Insel TR. The NIMH experimental medicine initiative. World
 1185 Psychiatry. 2015;14(2):151-3.
- 1186 89. National Institute of Mental Health. Strategic Plan Goals 2022
- 1187 [Available from: <u>https://www.nimh.nih.gov/about/strategic-planning-</u>
- 1188 <u>reports</u>.

Table 1. Schedule of Enrollment, Interventions, and Assessments

							Study per	iod					_	
TP' and a start	Screening	Baseline and treatment 1			D	aily aTBS	treatments	s and psycl	hotherapy				Post- treatment visit	Monthly follow-up visit
Imepoint	-t ₁	0	t ₁	t ₂	t ₃	t4 t5		t6	t7	t7 t8		t 10	t ₁₁	
Enrollment														
Medical history	Х													
screen														
Informed assent	Х													
and consent														
Physical	Х													
examination														
Vital signs	Х												Х	
Urine drug screen	Х													
Urine pregnancy screen (if applicable)	Х													
Pubertal Development Scale (self- assessment)	Х													
TASS	Х													
ATHF	Х													
Interventions														
Daily aTBS or			Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		
sham treatments														
Psychotherapy			Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		
Assessments														
Auditory		Х											Х	
threshold														
NIH Toolbox Mini-		Х											Х	
Neuropsychiatri c Interview for Children and	Х													

Adolescents (MINI- KID); adult version used if aged 18														
y Duis CA CC sting														
Personality Scale	Х													
Young Mania Rating Scale (YMRS)	Х	Х	Xª	Xª	Xa	Xa	Xa	Xª	Xª	Xa	Xa	Xa	Xª	Xª
Children's Depression Rating Scale Revised (CDRS-R)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Columbia– Suicide Severity Rating Scale (C-SSRS)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Beck Depression Inventory-II (BDI-II)	Х	Х											Х	Х
Pre/Post Treatment Expectations and Experience Questionnaire (adolescent and parent)		Х											Х	
Clinical Global Impressions– Severity Scale (CGI-S)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
TMS-EEG measures		Х											Х	
TMS-EMG		Х											Х	

	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Case report forms Adverse events	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Serious adverse events	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Concurrent psychotherapy	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Concurrent medications	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Hospitalizations related to suicidality noted														Х
Emergency department visits related to														Х
suicidality noted														

91 92 93 94 95 Abbreviations: aTBS, accelerated theta burst stimulation; ATHF, Antidepressant Treatment History Form; NIH, National Institutes of Health; t, timepoint; TASS, Transcranial Magnetic Stimulation Safety Screen; TMS-EEG, transcranial magnetic stimulation and electroencephalography; TMS-EMG, transcranial magnetic stimulation and electromyography;

X, occurs at that time. ^a If symptoms of mania occur.

96

It is made available under a CC-BY 4.0 International license .

Table 2. Description of Assessments

1197

Assessment	Description
Antidepressant	Systematic documentation of prior psychotropic
Treatment History	medication exposure and to quantify treatment
Form (ATHF)	resistance (No. of failed antidepressant trials with an
	adequate dose and duration)
Auditory thresholds	Audiometry testing
Beck Depression	Validated, 21-item, self-report measure with a score
Inventory-II (BDI-II)	range of 0-63
Brief Affective	Validated 33-item, self-report measure collected to
Neuroscience	assess behavioral characteristics in 6 affective
Personality Scale	neurobiological systems (play, seek, care, fear,
	anger, sadness)
Children's Depression	Validated, 17-item, clinician-rated tool to assess
Rating Scale Revised	severity of depression, with total possible scores
(CDRS-R)	ranging from 17 to 113; parents provide input into 14
	of the items
Clinical Global	A standard measure of symptom severity and
Impressions- Severity	treatment response
Scale (CGI-S)	
Columbia-Suicide	Validated, clinician-rated tool collected to assess
Severity Rating Scale	lifetime and ongoing suicidal ideation and behavior;
(C-SSRS)	scale's severity of ideation subscale is a 5-point
	ordinal scale that is the primary clinical outcome
	measure for this study

Mini-International	Structured psychiatric interview (MINI-KID for ages
Neuropsychiatric	12-17 y and MINI for ≥ 18 y) done to confirm
Interview for Children	diagnostic inclusion criteria and to rule out
and Adolescents	diagnostic exclusion criteria
(MINI-KID) and Mini-	
International	
Neuropsychiatric	
Interview (MINI)	
NIH Toolbox Cognition	Battery of cognitive tests recommended for ages \geq 7 y;
Battery	consists of tests of multiple constructs; it yields
	individual measure scores and these summary scores:
	Education, Handedness, Attention (Flanker
	Inhibitory Control and Attention Test), Episodic
	Memory (Picture Sequence Memory Test, and
	Auditory Verbal Learning Test), Executive Function
	(Dimensional Change Card Sort Test, Flanker
	Inhibitory Control and Attention Test), Language
	(Picture Vocabulary Test, Oral Reading Recognition
	Test), Processing Speed (Pattern Comparison
	Processing Speed Test), Working Memory (List
	Sorting Working Memory Test)
Pre/Post Treatment	Assessment of patient and parent impressions and
Expectations and	expectations and integrity of blinding by asking
Experience	adolescents and parents to guess their study arm
Questionnaire	assignment
(adolescent and parent)	

It is made available under a CC-BY 4.0 International license .

Pubertal Development	Self-report questionnaire and line drawings used to
Scale and Tanner	evaluate level of pubertal development
staging	
Transcranial Magnetic	Safety screen completed before TMS to confirm
Stimulation Safety	patient safety for TMS
Screen (TASS)	
Young Mania Rating	An 11-item measure used to assess for manic
Scale (YMRS)	symptoms; if the YMRS is positive, a MINI or
	MINI-KID will be repeated to evaluate for mania,
	and if the study participant meets full DSM-5 criteria
	for mania or hypomania, that person will be
	discontinued from the study and followed up
	clinically
TMS neurophysiology	TMS-EMG (LICI-100) and TMS-EEG (N45 and
measures	N100) neurophysiology measures (biomarkers of
	cortical inhibition and activity)
Abbreviations: aTBS, a	ccelerated theta burst stimulation; DSM-5, Diagnostic and
Statistical Manual of M	ental Disorders (Fifth Edition); LICI-100, long-interval
intracortical inhibition a	t an interstimulus interval of 100 ms; NIH, National Institutes

1201 of Health; N45, 45 ms after stimulation; N100, 100 ms after stimulation; TMS,

1202 transcranial magnetic stimulation; TMS-EEG, TMS and electroencephalography;

1203 TMS-EMG, TMS and electromyography.

1204

1198

1199

1200

1205 **Box.** Inclusion and Exclusion Criteria

Inclusion criteria:

- Age 12-18 y
- Willingness and ability to give informed consent if aged 18 y or if
 <18 y, to assent (with consent given by a parent or legal guardian)
- Diagnosis of major depressive disorder (MDD) based on the criteria of the *Diagnostic and Statistical Manual for Mental Disorders* (Fifth Edition) for all participants and at screening the Mini-International Neuropsychiatric Interview (MINI) for Children and Adolescents (MINI-KID) for participants aged 12-17 or the MINI for participants who are 18
- Current episode of MDD lasting at least 4 weeks but <3 y
- Depressive symptom severity as shown by a total Children's Depression Rating Scale Revised (CDRS-R) score ≥40
- Suicidal ideation score \geq 3 on item 13 of the CDRS-R
- Minimum score of 1 ("wish to be dead") on the Columbia–Suicide Severity Rating Scale (C-SSRS) severity of ideation subscale
- No demonstrated improvement by 25% or more in depressive symptom severity between screening evaluation and baseline
- Eligibility for transcranial magnetic stimulation (TMS) based on safety criteria
- Willingness to use a medically acceptable form of birth control during the 10-d treatment course if female and of childbearing potential

Exclusion criteria:

- Diagnosis of a psychotic disorder, bipolar disorder, anorexia nervosa, bulimia nervosa, or substance use disorder (except caffeine and tobacco) within the past year
- Lifetime diagnosis of a psychotic disorder, including schizophrenia, MDD with psychotic features, and bipolar disorder with psychotic features, confirmed by a research screening interview
- IQ <70^a
- Positive urine drug screen at baseline
- History of epilepsy or unexplained seizures or any other neurologic condition that includes a history of seizures
- Family history of epilepsy
- Use of medications that lower the seizure threshold (eg, neuroleptic agents and tricyclic antidepressants)
- History of any treatment with electroconvulsive therapy or TMS
- Use of any investigational drug within 4 wk of baseline
- Prior brain surgery
- Risk of increased intracranial pressure (eg, brain tumor) or a history of increased intracranial pressure
- Lifetime history of head trauma with loss of consciousness for >5 min
- Any true-positive findings on the Transcranial Magnetic Stimulation Safety Screen
- Pregnancy or nursing
- Conductive, ferromagnetic, or other magnetic-sensitive metals in the head within 30 cm of the treatment coil (excluding the mouth) that cannot be safely removed (eg, cochlear implants, vagus nerve

It is made available under a CC-BY 4.0 International license .

stimulators, deep brain stimulators, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, and hair barrettes)

- Any implanted stimulator or other implant controlled by physiologic signals, including a vagus nerve stimulator, spinal cord stimulator, peripheral nerve stimulator, defibrillator, or pacemaker
- Implanted medication pump
- Cerebrovascular disease, cerebral aneurysm, dementia, movement disorder, or repetitive or severe head trauma, or primary or secondary tumors in the central nervous system
- History of severe headaches within the previous year
- Vascular, traumatic, tumoral, infectious, or metabolic lesions of the brain, even without a history of seizure or without anticonvulsant medication
- An unstable medical illness
- Improvement in depressive symptom severity between screening and baseline by ≥25%
- Inability to adhere to the protocol
- ^a If a clinical concern exists about IQ, participants will be
- 1207 psychometrically assessed with the Slosson Intelligence Test–Revised,
- 1208 3rd edition (Slosson RL. Slosson Intelligence Test-Revised. 3rd ed.
- 1209 Revised by Nicholson CL, Hibpshman TL, Supplementary Manual by
- 1210 Larson S. East Aurora, NY: Slosson Educational Publications Inc).

It is made available under a CC-BY 4.0 International license .

Legend

1212 **Figure.** Study Schema.

1211

- 1213 aTBS, accelerated theta burst stimulation; CDRS-R, Children's Depression
- 1214 Rating Scale Revised; C-SSRS, Columbia–Suicide Severity Rating Scale;
- 1215 LICI, long-interval intracortical inhibition; MINI, Mini-International
- 1216 Neuropsychiatric Interview; N45, TMS-EEG evoked potential at 45
- 1217 milliseconds; N100, TMS-EEG evoked potential at 100 milliseconds; TBS,
- 1218 theta burst stimulation; TMS-EEG, transcranial magnetic stimulation and
- 1219 electroencephalography; TMS-EMG, transcranial magnetic stimulation and
- 1220 electromyography.



Figure